帕妥昔單抗銷售預測及市場規模分析（2034 年）

推動帕妥索汀成長的關鍵因素

1. 擴大市場佔有率並增加新患者數量

• Paltusotine 被定位為治療肢端肥大症的潛在First-in-Class口服療法，而目前市場主要由長效注射以生長抑制素受體配體 (SRL) 主導。
• 內分泌科醫生的濃厚興趣表明未來有潛力吸引新患者，尤其是在尋求慢性注射療法替代方案的患者群體中。
• 預計每日一次的口服給藥方式將減輕治療負擔並提高依從性，核准後可望迅速廣泛應用。
• Crinetics Pharmaceuticals 專注於口腔疾病管理的商業策略和醫生教育工作有望促進該領域的快速發展。

2. 擴展至主要適應症

• 肢端肥大症（主要適應症）：帕妥索汀正在開發用於治療需要生化控制的肢端肥大症患者，包括先前接受過注射西羅莫司治療的患者。
• 維持治療：對於已達到生化控制的患者，該藥物有可能成為有利的維持治療選擇，並且一旦病情穩定，該藥物可以取代注射藥物。
• 廣泛的肢端肥大症患者群體：如果核准，帕妥索汀有可能用於廣泛的患者群體，包括那些無法充分或耐受注射療法的患者。
• 研發管線和生命週期機會包括更早用於治療和更長期的疾病管理策略。

3. 地理擴張

• Paltusotine 正在開發中，旨在實現全球商業化，最初的目標是美國和歐洲等主要內分泌市場。
• 亞太地區具有長期成長潛力，這得益於腦下垂體疾病診斷率的提高和獲得專業內分泌護理的機會改善。
• 未來區域擴張預計將透過與當地監管機構的合作以及在內分泌專科領域的夥伴關係來實現。

4. 新適應症的核准

• 成功獲得監管部門對肢端肥大症的核准，將大大擴展該疾病的治療選擇，而過去十年來，該領域的創新一直很有限。
• 帕妥索汀獨特的口服特性有可能重塑標準治療流程，並使其能夠隨著時間的推移擴展到更廣泛的患者亞群。
• 隨著更多監管里程碑的達成以及在美國以外市場提交申請，未來收入來源有望進一步多元化。

5.肢端肥大症交易量強勁成長

• 肢端肥大症是一種慢性終身疾病，需要持續治療，因此預計治療需求將保持穩定。
• 患者和醫生對注射療法的不滿，正在催生對口服替代療法的潛在需求，這為口服療法提供了很高的普及潛力。
• 更新的臨床數據支持強力的生化控制（IGF-1 正常化），進一步增強了人們對長期使用的信心。

6. 競爭優勢與市場趨勢

• 帕妥索汀是一種口服小分子生長抑制素受體 2 型 (SST2)促效劑，其特性與注射緩釋製劑有顯著差異。
• 這種藥物可望提高患者的生活品質，減少就醫次數，並增強患者的治療自主性。
• 更廣泛的市場趨勢，例如以患者為中心的護理、對口服療法的偏好以及對長期疾病管理的最佳化，都有力地支持了帕妥昔汀的市場定位。
• 預計在罕見內分泌疾病領域更多地使用真實世界數據 (RWE) 將有助於提高支付方和處方醫生在核准後的信心。

帕妥索汀的最新進展

• 2025年11月，Crinetics Pharmaceuticals宣布，首例患者已隨機分配至3期CAREFNDR研究。該研究是一項多中心、隨機、雙盲、安慰劑對照試驗，旨在評估每日一次口服帕妥昔汀治療由分化良好的神經內分泌腫瘤引起的類癌症候群成年患者的療效和安全性。這項3期研究建立在2期研究的積極數據之上，2期研究顯示帕妥昔汀能夠快速且持續地降低類癌症候群症狀的頻率和嚴重程度，包括潮紅發作和排便次數增多。
• 2025年9月，Crinetics Pharmaceuticals公司宣布，美國食品藥物管理局（FDA）批准了Parsonify（核准）作為第一線治療藥物，用於治療對傳統療法反應不佳或不適合手術的成人肢端肥大症患者。 Parsonify是一種選擇性生長抑制素受體2型（SST2）非胜肽促效劑，成為首個核准用於治療成人肢端肥大症的每日一次口服藥物。

《帕妥索汀銷售預測及市場規模分析（2034）》報告全面深入地分析了帕妥索汀在七個主要國家（美國、四個歐盟國家（德國、法國、義大利和西班牙））的核准適應症－肢端肥大症以及潛在適應症－惡性類癌症候群的市場狀況。本報告詳細分析了帕妥索汀在七個主要國家（美國、四個歐盟國家（德國、法國、義大利和西班牙）、英國和日本）核准預測和市場表現，研究週期為2020年至2034年。報告也詳細描述了帕妥索汀在核准和潛在適應症中的具體應用。此外，本帕妥索汀市場報告還深入探討了帕妥索汀的研發及其他相關活動，包括銷售預測、作用機制、劑量和給藥途徑以及監管里程碑。此外，該報告還詳細分析了帕妥索汀的過去和現在的市場表現、未來市場評估（包括對七個主要國家已通過核准和潛在適應症的帕妥索汀市場進行預測分析）、SWOT分析、分析師觀點、市場競爭對手的全面概述，以及針對每種適應症的其他新興治療方法的概述。該報告還對帕妥索汀的銷售額及其市場促進因素進行了預測分析。

帕妥索汀藥物概述

帕妥昔汀（商品名：Parsonify）是由Crinetics Pharmaceuticals公司研發的一種新型非胜肽生長抑制素受體2型（SST2）促效劑。它是首個用於治療肢端肥大症的每日一次口服藥物。帕妥昔汀選擇性地與腦下垂體生長激素細胞上的SST2受體結合，抑制生長激素（GH）分泌，降低胰島素樣生長因子1（IGF-1）水平，從而實現生化控制，並緩解對手術反應不佳或不適合手術的成人肢端肥大症患者的頭痛、關節痛、出汗、疲勞和水腫等症狀。該藥於2025年9月25日獲得美國食品藥物管理局（FDA）核准。 PATHFNDR-1和PATHFNDR-2 III期臨床試驗表明，帕妥昔汀能夠快速且持續地使IGF-1水平恢復正常，並改善肢端肥大症症狀日記所記錄的症狀。該藥物有 20 毫克和 30 毫克兩種規格的片劑，使用時需監測高血糖、低血糖和心血管不良反應。本報告涵蓋帕妥索汀的銷售情況、成長障礙和促進因素、上市後狀況以及在多種適應症中的核准情況。

Paltusotine 目前處於 III 期臨床開發階段，用於治療惡性類癌症候群患者（NCT07087054）。

帕圖索汀市場報告範圍

本報告提供以下資訊：

• 對帕妥索汀進行全面的產品概述，包括其作用機制（MoA）、產品說明、劑量和給藥方法，以及核准適應症（例如肢端肥大症）和潛在適應症（例如惡性類癌症候群）的研究和開發活動。
• 本市場報告提供了有關 Paltusotine 監管里程碑和其他開發活動的詳細資訊。
• 該報告還重點介紹了帕妥索汀的成本估算和區域差異、已報告和估計的銷售額，以及在美國、歐洲和日本已已通過核准和潛在適應症的研發活動。
• 帕妥索汀市場報告還涵蓋專利資訊、學名藥上市及其對降低成本的影響。
• 本報告包括帕托索汀在已通過核准和潛在適應症方面的當前和預測銷售情況，直至 2034 年。
• 此外，也全面介紹了每種適應症的後期新興治療方法。
• Paltusotine 市場報告還包括對 Paltusotine已通過核准和潛在適應症的 SWOT 分析和分析師觀點。

調查方法：

這份帕圖索汀市場報告主要基於從內部資料庫、一手和二手研究以及DelveInsight產業專家團隊的內部分析中獲得的數據和資訊。二級資訊來源資訊和資料來自各種印刷和非印刷管道，例如搜尋引擎、新聞網站、全球監管機構網站、行業期刊、白皮書、雜誌、書籍、行業協會、貿易入口網站以及對現有資料庫的存取。

DelveInsight 對帕爾圖索汀的分析觀點

• 帕妥索汀的詳細市場評估

本市場預測報告對帕妥索汀在七個主要市場（美國、四個歐盟國家（德國、法國、義大利、西班牙）、英國和日本）的市場狀況進行了詳細評估，涵蓋其核准的適應症——肢端肥大症，以及潛在的適應症——惡性類癌症候群。報告的這一部分提供了帕妥索汀截至2034年的當前銷售數據和預測銷售數據。

• 帕妥索汀的臨床評價

Paltusotine 市場報告提供了有關 Paltusotine已通過核准和潛在適應症的臨床試驗資訊，包括研究干預措施、研究條件、實驗狀況以及開始和完成日期。

帕爾圖索汀的競爭格局

本報告深入分析了該領域的競爭對手和市售產品，並概述了新興產品及其預計上市日期，這些產品將推動市場出現激烈的競爭。

帕妥索汀的市場潛力和收入預測

• 帕妥索汀及其主要適應症的預期市場規模
• Paltusotine 的預計銷售潛力（銷售尖峰時段預測）
• 帕妥昔單抗定價策略與報銷環境

帕妥索汀的競爭訊息

• 在研競爭藥物數量（研發管線分析）
• 帕妥索汀與現有治療方法相比的市場定位
• 與競爭對手相比，帕妥索汀的優勢和劣勢

帕妥索汀監管和商業里程碑

• 帕妥索汀的關鍵監管核准和預計上市時間
• 商業合作、授權協議和併購活動

帕妥索汀的臨床鑑別診斷

• 與現有藥物相比，帕妥索汀具有更優的療效和安全性
• 帕圖索汀的獨特優勢

帕圖索汀市場報告要點

• 未來幾年，隨著帕妥索汀的廣泛應用、處方箋的增加以及在多種免疫適應症中的更廣泛應用，其市場格局可能會發生變化，這將推動市場規模的成長。
• Paltusotine相關企業正在開發以治療和改善疾病狀態的新方法為重點的治療方法，以評估可能影響 paltusotine 優勢的挑戰和機會。
• 其他用於治療肢端肥大症的新興產品，以及惡性類癌症候群等潛在適應症，預計將對帕妥索汀構成激烈的市場競爭，而近期推出的後期治療方法預計將對市場產生重大影響。
• 對監管里程碑和開發活動的詳細說明，提供了帕妥索汀在已通過核准和潛在適應症中的當前開發狀態。
• 分析帕妥索汀的成本、定價趨勢和市場定位，以支持免疫學領域的策略決策。
• 我們對 2034 年之前帕妥索汀銷售預測數據的詳細分析，將透過確定帕妥索汀在已通過核准和潛在適應症中的整體情況，幫助我們的客戶進行治療組合決策流程。

目錄

第1章 報告概述

2. 帕妥索汀核准適應症概述（包括肢端肥大症）和潛在適應症概述（包括惡性類癌症候群）

• 產品詳情
• 帕妥索汀的臨床開發
  • 帕妥索汀的臨床研究
  • 帕妥索汀臨床試驗資訊
  • 安全性和有效性
• 其他發展活動
• 產品簡介

第3章 帕妥索汀的競爭格局（已上市治療方法）

第4章 競爭格局（後期新型帕托索汀療法）

第5章 帕圖索欣市場評估

• 帕妥索汀市場展望（已通過核准和潛在適應症）
• 對七個主要國家的分析
  • 帕妥昔單抗在七個主要國家已已通過核准和潛在適應症的市場規模
• 各國市場
  • 帕妥索汀在美國已通過核准和潛在適應症的市場規模
  • 帕妥索汀在德國的市場規模（已通過核准和潛在適應症）
  • 帕妥索汀在英國已已通過核准和潛在適應症的市場規模

第6章 帕圖索欽的SWOT分析

第7章 分析師觀點

第8章附錄

• 參考
• 報告調查方法

第9章 DelveInsight 服務

第10章 免責聲明

第11章 關於 DelveInsight

第12章 報告購買選項

Key Factors Driving Paltusotine Growth

1. Market Share Gains and New Patient Starts

• Paltusotine is positioned as a potential first-in-class oral therapy for acromegaly, targeting a market currently dominated by long-acting injectable somatostatin receptor ligands (SRLs).
• Strong interest from endocrinologists suggests meaningful future new patient starts, particularly among patients seeking alternatives to chronic injections.
• The oral, once-daily profile is expected to lower treatment burden and improve persistence, which could translate into faster uptake following approval.
• Crinetics Pharmaceuticals' focused commercial strategy and physician education efforts around oral disease control are expected to support early adoption.

2. Expansion Across Key Indications

• Acromegaly (Primary Indication): Paltusotine is being developed for patients with acromegaly who require chronic biochemical control, including those previously treated with injectable SRLs.
• Maintenance Therapy: The drug is well positioned as a maintenance option for biochemically controlled patients, potentially replacing injectables in stable disease.
• Broad Acromegaly Population: If approved, paltusotine may be used across a wide range of patients, including those inadequately controlled or intolerant to injections.
• Pipeline and lifecycle opportunities may include earlier-line use and long-term disease management strategies.

3. Geographic Expansion

• Paltusotine is being developed with a global commercialization outlook, initially targeting major endocrine markets such as the United States and Europe.
• Asia-Pacific represents a long-term growth opportunity, supported by increasing diagnosis rates of pituitary disorders and improving access to specialist endocrine care.
• Future geographic expansion is expected to be supported by local regulatory engagement and specialty endocrinology partnerships.

4. New Indication Approvals

• Successful regulatory approval for acromegaly would significantly broaden treatment options in a market with limited innovation over the past decade.
• Paltusotine's differentiated oral profile could reshape standard-of-care algorithms, enabling label expansion across broader patient subgroups over time.
• Additional regulatory milestones and submissions in ex-US markets would further diversify future revenue streams.

5. Strong Acromegaly Volume Momentum

• Acromegaly remains a chronic, lifelong condition, requiring sustained treatment and driving consistent therapy volumes.
• Patient and physician dissatisfaction with injections is creating latent demand for oral alternatives, supporting strong uptake potential.
• Clinical updates have reinforced robust biochemical control (IGF-1 normalization), supporting confidence in long-term use.

6. Competitive Differentiation and Market Trends

• Paltusotine's oral small-molecule somatostatin receptor type 2 (SST2) agonist profile strongly differentiates it from injectable depot formulations.
• The drug offers the potential for improved quality of life, reduced clinic visits, and greater treatment autonomy.
• Broader market trends-such as patient-centric care, preference for oral therapies, and long-term disease management optimization-strongly support Paltusotine's positioning.
• Increasing use of real-world evidence (RWE) in rare endocrine disorders is expected to reinforce payer and prescriber confidence post-approval.

Paltusotine Recent Developments

• In November 2025, Crinetics Pharmaceuticals announced the first patient had been randomized in the pivotal Phase III CAREFNDR trial, a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of once-daily, oral paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The Phase III study builds on positive Phase II data in which paltusotine demonstrated rapid and sustained reductions in the frequency and severity of carcinoid syndrome symptoms, including flushing episodes and bowel movements.
• In September 2025, Crinetics Pharmaceuticals announced that the US Food and Drug Administration (FDA) approved PALSONIFY (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY, a selectively-targeted somatostatin receptor type 2 nonpeptide (SST2) agonist, is now the first once-daily, oral treatment approved for adults with acromegaly.

"Paltusotine Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Paltusotine for approved indication like Acromegaly; and potential indication like Malignant carcinoid syndrome in the 7MM. A detailed picture of Paltusotine's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Paltusotine for approved and potential indications. The Paltusotine market report provides insights about Paltusotine's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Paltusotine performance, future market assessments inclusive of the Paltusotine market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Paltusotine sales forecasts, along with factors driving its market.

Paltusotine Drug Summary

Paltusotine, marketed as PALSONIFY, is a novel non-peptide somatostatin receptor type 2 (SST2) agonist developed by Crinetics Pharmaceuticals as the first once-daily oral therapy for acromegaly. It selectively binds to SST2 receptors on pituitary somatotrophs, inhibiting growth hormone (GH) secretion and reducing insulin-like growth factor 1 (IGF-1) levels, thereby achieving biochemical control and alleviating symptoms like headaches, joint pain, sweating, fatigue, and swelling in adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. FDA-approved on September 25, 2025, based on PATHFNDR-1 and PATHFNDR-2 Phase 3 trials showing rapid, durable IGF-1 normalization and symptom improvement via the Acromegaly Symptom Diary, it is available as 20 mg and 30 mg tablets with monitoring for hyperglycemia, hypoglycemia, and cardiac effects. The report provides Paltusotine's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Paltusotine is in the Phase III stage of clinical development for the treatment of patients with Malignant carcinoid syndrome (NCT07087054).

Scope of the Paltusotine Market Report

The report provides insights into:

• A comprehensive product overview including the Paltusotine MoA, description, dosage and administration, research and development activities in approved indication like Acromegaly; and potential indication like Malignant carcinoid syndrome.
• Elaborated details on Paltusotine regulatory milestones and other development activities have been provided in Paltusotine market report.
• The report also highlights Paltusotine's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Paltusotine market report also covers the patents information, generic entry and impact on cost cut.
• The Paltusotine market report contains current and forecasted Paltusotine sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Paltusotine market report also features the SWOT analysis with analyst views for Paltusotine in approved and potential indications.

Methodology:

The Paltusotine market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Paltusotine Analytical Perspective by DelveInsight

• In-depth Paltusotine Market Assessment

This Paltusotine sales market forecast report provides a detailed market assessment of Paltusotine for approved indication like Acromegaly; and potential indication like Malignant carcinoid syndrome in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Paltusotine sales data uptil 2034.

• Paltusotine Clinical Assessment

The Paltusotine market report provides the clinical trials information of Paltusotine for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Paltusotine Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Paltusotine Market Potential & Revenue Forecast

• Projected market size for the Paltusotine and its key indications
• Estimated Paltusotine sales potential (Paltusotine peak sales forecasts)
• Paltusotine Pricing strategies and reimbursement landscape

Paltusotine Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Paltusotine Market positioning compared to existing treatments
• Paltusotine Strengths & weaknesses relative to competitors

Paltusotine Regulatory & Commercial Milestones

• Paltusotine Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Paltusotine Clinical Differentiation

• Paltusotine Efficacy & safety advantages over existing drugs
• Paltusotine Unique selling points

Paltusotine Market Report Highlights

• In the coming years, the Paltusotine market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Paltusotine companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Paltusotine's dominance.
• Other emerging products for Acromegaly; and potential indication like Malignant carcinoid syndrome are expected to give tough market competition to Paltusotine and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Paltusotine in approved and potential indications.
• Analyse Paltusotine cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Paltusotine sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Paltusotine in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Paltusotine? How strong is Paltusotine's clinical and commercial performance?
• What is Paltusotine's clinical trial status in each individual indications such as Acromegaly; and potential indication like Malignant carcinoid syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Paltusotine Manufacturers?
• What are the key designations that have been granted to Paltusotine for approved and potential indications? How are they going to impact Paltusotine's penetration in various geographies?
• What is the current and forecasted Paltusotine market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Paltusotine in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Paltusotine for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Paltusotine? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Paltusotine Overview in approved indication like Acromegaly; and potential indication like Malignant carcinoid syndrome

• 2.1. Product Detail
• 2.2. Paltusotine Clinical Development
  • 2.2.1. Paltusotine Clinical studies
  • 2.2.2. Paltusotine Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Paltusotine Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Paltusotine Therapies)

5. Paltusotine Market Assessment

• 5.1. Paltusotine Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. Paltusotine Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Paltusotine Market Size in the United States for approved and potential indications
  • 5.3.2. Paltusotine Market Size in Germany for approved and potential indications
  • 5.3.3. Paltusotine Market Size in France for approved and potential indications
  • 5.3.4. Paltusotine Market Size in Italy for approved and potential indications
  • 5.3.5. Paltusotine Market Size in Spain for approved and potential indications
  • 5.3.6. Paltusotine Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. Paltusotine Market Size in Japan for approved and potential indications

6. Paltusotine SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

List of Tables

• Table 1: Paltusotine, Clinical Trial Description, 2023
• Table 2: Paltusotine, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Paltusotine's pricing and cost Assumptions
• Table 6: Paltusotine's Sales Analysis in the 7MM, in USD million (2020-2034)
• Table 7: Paltusotine Market Size in the US, in USD million (2020-2034)
• Table 8: Paltusotine Market Size in Germany, in USD million (2020-2034)
• Table 9: Paltusotine Market Size in France, in USD million (2020-2034)
• Table 10: Paltusotine Market Size in Italy, in USD million (2020-2034)
• Table 11: Paltusotine Market Size in Spain, in USD million (2020-2034)
• Table 12: Paltusotine Market Size in the UK, in USD million (2020-2034)
• Table 13: Paltusotine Market Size in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: Paltusotine's Sales Analysis in the 7MM, USD million (2020-2034)
• Figure 2: Paltusotine Market Size in the United States, USD million (2020-2034)
• Figure 3: Paltusotine Market Size in Germany, USD million (2020-2034)
• Figure 4: Paltusotine Market Size in France, USD million (2020-2034)
• Figure 5: Paltusotine Market Size in Italy, USD million (2020-2034)
• Figure 6: Paltusotine Market Size in Spain, USD million (2020-2034)
• Figure 7: Paltusotine Market Size in the United Kingdom, USD million (2020-2034)
• Figure 8: Paltusotine Market Size in Japan, USD million (2020-2034)